{
    "info": {
        "nct_id": "NCT06065748",
        "official_title": "A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy",
        "inclusion_criteria": "* Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent\n* Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)\n* Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing\n* Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after >/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse occurred >/=12 months since completion).\n* No prior systemic anti-cancer therapy for advanced disease\n* Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1\n* For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer\n* Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents\n* Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term\n* Active cardiac disease or history of cardiac dysfunction\n* Clinically significant history of liver disease",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment",
            "criterions": [
                {
                    "exact_snippets": "pre/perimenopausal women",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "pre-menopausal",
                                "perimenopausal"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "men",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment",
                    "criterion": "LHRH agonist therapy",
                    "requirements": [
                        {
                            "requirement_type": "willingness to undergo and maintain treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "approved LHRH agonist"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced or metastatic adenocarcinoma of the breast",
                    "criterion": "adenocarcinoma of the breast",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to treatment with curative intent",
                    "criterion": "treatment with curative intent",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after >/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse occurred >/=12 months since completion).",
            "criterions": [
                {
                    "exact_snippets": "Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after >/=12 months or off-treatment within 12 months of completion.",
                    "criterion": "resistance to prior adjuvant endocrine therapy (ET)",
                    "requirements": [
                        {
                            "requirement_type": "resistance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relapse timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior use of adjuvant CDK4/6i is allowed (if relapse occurred >/=12 months since completion).",
                    "criterion": "prior use of adjuvant CDK4/6 inhibitor (CDK4/6i)",
                    "requirements": [
                        {
                            "requirement_type": "prior use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relapse timing since completion",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior systemic anti-cancer therapy for advanced disease",
            "criterions": [
                {
                    "exact_snippets": "No prior systemic anti-cancer therapy for advanced disease",
                    "criterion": "prior systemic anti-cancer therapy for advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing",
            "criterions": [
                {
                    "exact_snippets": "Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing",
                    "criterion": "ESR1 mutation status in baseline circulating tumor DNA (ctDNA)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "testing_method",
                            "expected_value": "central laboratory testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined per RECIST v.1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "measurable per RECIST v.1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "non-measurable (including bone-only) disease",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "non-measurable (including bone-only)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)",
            "criterions": [
                {
                    "exact_snippets": "Documented estrogen receptor-positive (ER+)",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-negative (HER2-) tumor",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)",
                    "criterion": "tumor sample availability",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": [
                                "most recent tumor biopsy",
                                "archived tumor sample if a recent tumor sample is not available"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Clinically significant history of liver disease",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant history of liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active cardiac disease or history of cardiac dysfunction",
            "criterions": [
                {
                    "exact_snippets": "Active cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of cardiac dysfunction",
                    "criterion": "cardiac dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with another SERD (e.g., fulvestrant, oral SERDs)",
                    "criterion": "prior treatment with SERD",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "novel ER-targeting agents",
                    "criterion": "prior treatment with novel ER-targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer",
                    "criterion": "prior systemic therapy for locally advanced unresectable or metastatic breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term",
            "criterions": [
                {
                    "exact_snippets": "Advanced, symptomatic, visceral spread",
                    "criterion": "visceral spread",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at risk of life-threatening complications in the short term",
                    "criterion": "risk of life-threatening complications in the short term",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}